PCM
GILD icon

Prelude Capital Management’s Gilead Sciences GILD Stock Holding History

Prelude Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$248K Buy
+1,783
New +$250K 0.02% 801
2025
Q3 		– Sell
-9,264
Closed -$1.03M – 1244
2025
Q2 		$1.03M Buy
9,264
+6,803
+276% +$724K 0.1% 252
2025
Q1 		$276K Sell
2,461
-8,099
-77% -$836K 0.02% 741
2024
Q4 		$975K Sell
10,560
-3,920
-27% -$353K 0.06% 389
2024
Q3 		$1.21M Buy
+14,480
New +$1.1M 0.07% 332
2022
Q2 		– Sell
-5,488
Closed -$326K – 1896
2022
Q1 		$326K Sell
5,488
-12,467
-69% -$797K 0.01% 1045
2021
Q4 		$1.3M Buy
+17,955
New +$1.24M 0.03% 487
2021
Q2 		– Sell
-22,921
Closed -$1.48M – 1748
2021
Q1 		$1.48M Buy
22,921
+14,875
+185% +$959K 0.04% 442
2020
Q4 		$469K Buy
8,046
+1,106
+16% +$66.7K 0.01% 745
2020
Q3 		$439K Sell
6,940
-1,317
-16% -$91.3K 0.02% 468
2020
Q2 		$635K Sell
8,257
-15,779
-66% -$1.21M 0.04% 419
2020
Q1 		$1.8M Buy
24,036
+11,220
+88% +$775K 0.12% 120
2019
Q4 		$833K Buy
+12,816
New +$835K 0.03% 440
2019
Q3 		– Sell
-29,524
Closed -$2M – 1824
2019
Q2 		$2M Buy
29,524
+6,401
+28% +$421K 0.1% 203
2019
Q1 		$1.5M Sell
23,123
-19,436
-46% -$1.29M 0.08% 244
2018
Q4 		$2.66M Buy
42,559
+22,769
+115% +$1.59M 0.18% 119
2018
Q3 		$1.53M Sell
19,790
-2,654
-12% -$200K 0.09% 254
2018
Q2 		$1.59M Buy
22,444
+17,432
+348% +$1.23M 0.1% 214
2018
Q1 		$378K Sell
5,012
-8,002
-61% -$636K 0.03% 512
2017
Q4 		$932K Buy
13,014
+3,648
+39% +$277K 0.07% 268
2017
Q3 		$759K Sell
9,366
-33,437
-78% -$2.56M 0.07% 286
2017
Q2 		$3.03M Buy
42,803
+6,377
+18% +$424K 0.29% 71
2017
Q1 		$2.47M Buy
36,426
+7,650
+27% +$538K 0.24% 102
2016
Q4 		$2.06M Buy
28,776
+2,044
+8% +$152K 0.25% 113
2016
Q3 		$2.12M Sell
26,732
-11,645
-30% -$946K 0.22% 91
2016
Q2 		$3.2M Sell
38,377
-851
-2% -$75.5K 0.45% 44
2016
Q1 		$3.6M Buy
39,228
+547
+1% +$49.3K 0.5% 25
2015
Q4 		$3.91M Buy
38,681
+3,040
+9% +$316K 0.61% 30
2015
Q3 		$3.5M Buy
35,641
+14,956
+72% +$1.66M 0.51% 36
2015
Q2 		$2.42M Buy
20,685
+1,338
+7% +$146K 0.34% 64
2015
Q1 		$1.9M Buy
19,347
+546
+3% +$55.4K 0.26% 88
2014
Q4 		$1.77M Sell
18,801
-6,400
-25% -$662K 0.26% 70
2014
Q3 		$2.68M Buy
25,201
+1,760
+8% +$172K 0.38% 36
2014
Q2 		$1.94M Buy
23,441
+5,670
+32% +$441K 0.26% 74
2014
Q1 		$1.26M Sell
17,771
-1,750
-9% -$137K 0.17% 137
2013
Q4 		$1.47M Buy
19,521
+2,000
+11% +$139K 0.24% 82
2013
Q3 		$1.1M Sell
17,521
-14,193
-45% -$848K 0.18% 116
2013
Q2 		$1.63M Buy
+31,714
New +$1.65M 0.35% 51

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Prelude Capital Management's GILD Position: Q1 2026 in Review

Prelude Capital Management opened a new position in Gilead Sciences (GILD) in Q1 2026: 1,783 shares worth $248K. The stake represents 0.02% of the portfolio and ranks #801 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in GILD as recently as Q2 2025.

Prelude Capital Management first reported a position in GILD in Q2 2013 and has held it in 38 quarters since. The position peaked at $3.91M in Q4 2015. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Prelude Capital Management held 1,783 shares of Gilead Sciences worth $248K as of Q1 2026.
  • Gilead Sciences was a new Prelude Capital Management position in Q1 2026.
  • Gilead Sciences made up 0.02% of Prelude Capital Management's portfolio in Q1 2026, its #801 holding.
  • Prelude Capital Management first reported a position in Gilead Sciences in Q2 2013 and has held it in 38 quarters since.
  • Prelude Capital Management's Gilead Sciences position peaked at $3.91M in Q4 2015.
  • 2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.